<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783377</url>
  </required_header>
  <id_info>
    <org_study_id>AROAPOC31001</org_study_id>
    <nct_id>NCT03783377</nct_id>
  </id_info>
  <brief_title>Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)</brief_title>
  <official_title>A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and
      in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment</measure>
    <time_frame>Up to Day 113 (+/- 3 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ARO-APOC3 in Normal Healthy Volunteers (NHVs): Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Single dose phase: Up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-APOC3 in NHVs: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Single dose phase: Up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-APOC3 in NHVs: Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Single dose phase: Up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-APOC3 in NHVs: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)</measure>
    <time_frame>Single dose phase: Up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-APOC3 in NHVs: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)</measure>
    <time_frame>Single dose phase: Up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Fasting Serum APOC3 from Pre-Dose Baseline</measure>
    <time_frame>Up to Day 113 (+/- 3 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Familial Chylomicronemia</condition>
  <arm_group>
    <arm_group_label>ARO-APOC3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-APOC3</intervention_name>
    <description>single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections</description>
    <arm_group_label>ARO-APOC3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sterile normal saline (0.9% NaCl)</intervention_name>
    <description>calculated volume to match active treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of childbearing potential must have a negative pregnancy test, cannot be
             breastfeeding and must be willing to use contraception

          -  Willing to provide written informed consent and to comply with study requirements

          -  Normal electrocardiogram (ECG) at screening

          -  Hypertriglyceridemic patients must have a history of fasting serum triglycerides of at
             least 300 mg/dL (3.38 mmol/L) at screening or verifiable diagnosis of FCS

        Exclusion Criteria:

          -  Clinically significant health concerns

          -  Regular use of alcohol within one month prior to Screening

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Recent use of illicit drugs

          -  Use of more than two tobacco/nicotine containing or cannabis products per month within
             6 months prior to drug administration (applicable only to Normal Healthy Volunteers)

        Note: additional inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>+1-626-304-3400</phone>
    <email>clinicaltrials@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Kearins</last_name>
      <phone>+61 2 95157236</phone>
      <email>Kerry.Kearins@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QPharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast Clinical Trial Centre</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Poechhacker</last_name>
      <email>spoechha@usc.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Laura Donnelly</last_name>
      <email>ldonnell@usc.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Thackwray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Healy</last_name>
      <phone>+61 409877807</phone>
      <email>Deanise.Healy@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Peter Clifton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Pluske</last_name>
      <phone>+61 427345182</phone>
      <email>rpluske@linear.org.au</email>
    </contact>
    <investigator>
      <last_name>Gerald Watts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sindy Desgagnes</last_name>
      <phone>418-545-1252</phone>
      <email>sindy.desgagnes@ecogene21.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Gaudet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute de Recherches Cliniques de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Thame</last_name>
      <phone>+ 64 9 373 3474</phone>
      <email>Olivia.Thame@clinicalstudies.co.nz</email>
    </contact>
    <investigator>
      <last_name>Christian Schwabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Papatoetoe</city>
        <state>Auckland</state>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Cassidy</last_name>
      <phone>+64 9 276 0044</phone>
      <email>Alice.Cassidy@mmclintrials.nz</email>
    </contact>
    <investigator>
      <last_name>John Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lipid &amp; Diabetes Research Group</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice McGregor</last_name>
      <phone>+64 3 364 1376</phone>
      <email>Patrice.McGregor@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Russell Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

